Newstral
Biogen
- Alzheimer’s program renewal on the way, lawmakers sayPOLITICO
- Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandalArs Technica
- Biogen Abandons Its Controversial Alzheimer’s Drug AduhelmWRAL
- Biogen to cease production of controversial Alzheimer's drugPOLITICO
- Biogen plans to shut down its controversial Alzheimer’s drug AduhelmSeattle Times
- FDA Approves Yet Another Interchangeable Biosimilar and Another Biosimilarjdsupra.com
- BOzempic mania fuels deal optimism across drug industrybloomberg.com
- China joins US and Japan in approving Alzheimer’s drug Leqembi developed by Eisai and BiogenSouth China Morning Post
- Flintshire leads in celebrating Wales Climate Weekdeeside.com
- New BPCIA Case Filed: Genentech and Biogen Want to Stop Dr. Reddy’s Rituximab Biosimilar from Entering the U.S. Marketjdsupra.com
- Genentech, Roche, and Biogen Sue Dr. Reddy’s and Fresenius for a Proposed Biosimilar of Rituxan in District of New Jerseyjdsupra.com
- BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Statusjdsupra.com
- There's a powerful new drug to treat postpartum depression — with a price tag most can't affordNew York Post
- Blockbuster Biologics Review | Issue 21jdsupra.com
- MAlzheimer’s drug Leqembi exhibits promise as injectionmvtelegraph.com
- FDA Approves Biogen Biosimilar for Genentech's Actemra®jdsupra.com
- Update on Ophthalmic Anti-VEGF Therapeuticsjdsupra.com
- The RealReal is hanging on by a threadNew York Post
- Biogen Announces FDA Approval of TOFIDENCE, a Tocilizumab Biosimilar Referencing ACTEMRAjdsupra.com
Frequent names
Newstral's extraction of names of people and organisations from the world's news is completely automated. If you do not want your name to appear here, please contact us. We will be happy to look at your request.